Physician profile
Sidney Raetz
NPI 1124689633
$716.39
in general payments reported to CMS, 2019-2025
20 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $145 · 2023: $158 · 2024: $97.47 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $118.58 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $85.12 | 2022-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $84.10 | 2021-2025 | |
| Lilly USA, LLC | $69.50 | 2021-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $63.07 | 2022 | |
| Glaxosmithkline, LLC. | $41.64 | 2021-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $29.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.92 | 2021 | |
| Corium, LLC | $25.29 | 2023 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $24.20 | 2021-2024 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.58 | 2023 | |
| Biocryst US Sales Co., LLC | $17.18 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.64 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $15.19 | 2024 | Auvelity |
| Pfizer INC. | $14.21 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $14.15 | 2021 | |
| Exact Sciences Corporation | $13.67 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $13.29 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.25 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Raetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.